nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Infusion site reaction—Paclitaxel—ovarian cancer	0.0416	0.0416	CcSEcCtD
Oritavancin—Infusion site reaction—Docetaxel—ovarian cancer	0.0353	0.0353	CcSEcCtD
Oritavancin—Extravasation—Carboplatin—ovarian cancer	0.028	0.028	CcSEcCtD
Oritavancin—Bilirubin total increased—Epirubicin—ovarian cancer	0.0183	0.0183	CcSEcCtD
Oritavancin—Bilirubin total increased—Doxorubicin—ovarian cancer	0.017	0.017	CcSEcCtD
Oritavancin—Induration—Paclitaxel—ovarian cancer	0.0144	0.0144	CcSEcCtD
Oritavancin—Anaemia—Altretamine—ovarian cancer	0.0143	0.0143	CcSEcCtD
Oritavancin—Hyperuricaemia—Chlorambucil—ovarian cancer	0.0136	0.0136	CcSEcCtD
Oritavancin—Extravasation—Topotecan—ovarian cancer	0.0128	0.0128	CcSEcCtD
Oritavancin—Blood uric acid increased—Chlorambucil—ovarian cancer	0.0128	0.0128	CcSEcCtD
Oritavancin—Extravasation—Melphalan—ovarian cancer	0.0126	0.0126	CcSEcCtD
Oritavancin—Blood bilirubin increased—Topotecan—ovarian cancer	0.0118	0.0118	CcSEcCtD
Oritavancin—Hyperuricaemia—Melphalan—ovarian cancer	0.0118	0.0118	CcSEcCtD
Oritavancin—Blood uric acid increased—Melphalan—ovarian cancer	0.0112	0.0112	CcSEcCtD
Oritavancin—Extravasation—Vinorelbine—ovarian cancer	0.011	0.011	CcSEcCtD
Oritavancin—Blood bilirubin increased—Vinorelbine—ovarian cancer	0.0101	0.0101	CcSEcCtD
Oritavancin—Infection—Carboplatin—ovarian cancer	0.00866	0.00866	CcSEcCtD
Oritavancin—Dizziness—Altretamine—ovarian cancer	0.00834	0.00834	CcSEcCtD
Oritavancin—Vomiting—Altretamine—ovarian cancer	0.00802	0.00802	CcSEcCtD
Oritavancin—Nausea—Altretamine—ovarian cancer	0.0075	0.0075	CcSEcCtD
Oritavancin—Extravasation—Paclitaxel—ovarian cancer	0.00738	0.00738	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Topotecan—ovarian cancer	0.00731	0.00731	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Topotecan—ovarian cancer	0.00716	0.00716	CcSEcCtD
Oritavancin—Cellulitis—Paclitaxel—ovarian cancer	0.00708	0.00708	CcSEcCtD
Oritavancin—Blood bilirubin increased—Paclitaxel—ovarian cancer	0.00681	0.00681	CcSEcCtD
Oritavancin—Bronchospasm—Melphalan—ovarian cancer	0.00676	0.00676	CcSEcCtD
Oritavancin—Infestation NOS—Topotecan—ovarian cancer	0.00626	0.00626	CcSEcCtD
Oritavancin—Infestation—Topotecan—ovarian cancer	0.00626	0.00626	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Vinorelbine—ovarian cancer	0.00626	0.00626	CcSEcCtD
Oritavancin—Extravasation—Docetaxel—ovarian cancer	0.00625	0.00625	CcSEcCtD
Oritavancin—Wheezing—Paclitaxel—ovarian cancer	0.00625	0.00625	CcSEcCtD
Oritavancin—Erythema multiforme—Chlorambucil—ovarian cancer	0.00597	0.00597	CcSEcCtD
Oritavancin—Bronchospasm—Vinorelbine—ovarian cancer	0.00591	0.00591	CcSEcCtD
Oritavancin—Blood bilirubin increased—Docetaxel—ovarian cancer	0.00577	0.00577	CcSEcCtD
Oritavancin—Connective tissue disorder—Melphalan—ovarian cancer	0.00541	0.00541	CcSEcCtD
Oritavancin—Infestation NOS—Vinorelbine—ovarian cancer	0.00535	0.00535	CcSEcCtD
Oritavancin—Infestation—Vinorelbine—ovarian cancer	0.00535	0.00535	CcSEcCtD
Oritavancin—Anaemia—Chlorambucil—ovarian cancer	0.00508	0.00508	CcSEcCtD
Oritavancin—Immune system disorder—Topotecan—ovarian cancer	0.00508	0.00508	CcSEcCtD
Oritavancin—Mediastinal disorder—Topotecan—ovarian cancer	0.00506	0.00506	CcSEcCtD
Oritavancin—Angioedema—Chlorambucil—ovarian cancer	0.00502	0.00502	CcSEcCtD
Oritavancin—Immune system disorder—Melphalan—ovarian cancer	0.00497	0.00497	CcSEcCtD
Oritavancin—Mediastinal disorder—Melphalan—ovarian cancer	0.00496	0.00496	CcSEcCtD
Oritavancin—Malnutrition—Topotecan—ovarian cancer	0.00489	0.00489	CcSEcCtD
Oritavancin—Hypoglycaemia—Paclitaxel—ovarian cancer	0.00479	0.00479	CcSEcCtD
Oritavancin—Connective tissue disorder—Vinorelbine—ovarian cancer	0.00472	0.00472	CcSEcCtD
Oritavancin—Abscess—Epirubicin—ovarian cancer	0.00465	0.00465	CcSEcCtD
Oritavancin—Anaemia—Topotecan—ovarian cancer	0.00452	0.00452	CcSEcCtD
Oritavancin—Angioedema—Topotecan—ovarian cancer	0.00447	0.00447	CcSEcCtD
Oritavancin—Cardiac disorder—Vinorelbine—ovarian cancer	0.00446	0.00446	CcSEcCtD
Oritavancin—Infection—Chlorambucil—ovarian cancer	0.00446	0.00446	CcSEcCtD
Oritavancin—Anaemia—Melphalan—ovarian cancer	0.00443	0.00443	CcSEcCtD
Oritavancin—Immune system disorder—Vinorelbine—ovarian cancer	0.00434	0.00434	CcSEcCtD
Oritavancin—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00433	0.00433	CcSEcCtD
Oritavancin—Abscess—Doxorubicin—ovarian cancer	0.0043	0.0043	CcSEcCtD
Oritavancin—Extravasation—Epirubicin—ovarian cancer	0.00422	0.00422	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Paclitaxel—ovarian cancer	0.00421	0.00421	CcSEcCtD
Oritavancin—Malnutrition—Vinorelbine—ovarian cancer	0.00418	0.00418	CcSEcCtD
Oritavancin—Myalgia—Topotecan—ovarian cancer	0.00416	0.00416	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00414	0.00414	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Paclitaxel—ovarian cancer	0.00412	0.00412	CcSEcCtD
Oritavancin—Myalgia—Melphalan—ovarian cancer	0.00408	0.00408	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00405	0.00405	CcSEcCtD
Oritavancin—Cellulitis—Epirubicin—ovarian cancer	0.00405	0.00405	CcSEcCtD
Oritavancin—Hyperuricaemia—Epirubicin—ovarian cancer	0.00397	0.00397	CcSEcCtD
Oritavancin—Infection—Topotecan—ovarian cancer	0.00397	0.00397	CcSEcCtD
Oritavancin—Nervous system disorder—Topotecan—ovarian cancer	0.00392	0.00392	CcSEcCtD
Oritavancin—Extravasation—Doxorubicin—ovarian cancer	0.0039	0.0039	CcSEcCtD
Oritavancin—Blood bilirubin increased—Epirubicin—ovarian cancer	0.00389	0.00389	CcSEcCtD
Oritavancin—Infection—Melphalan—ovarian cancer	0.00388	0.00388	CcSEcCtD
Oritavancin—Skin disorder—Topotecan—ovarian cancer	0.00388	0.00388	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00387	0.00387	CcSEcCtD
Oritavancin—Anaemia—Vinorelbine—ovarian cancer	0.00387	0.00387	CcSEcCtD
Oritavancin—Angioedema—Vinorelbine—ovarian cancer	0.00382	0.00382	CcSEcCtD
Oritavancin—Tachycardia—Melphalan—ovarian cancer	0.00382	0.00382	CcSEcCtD
Oritavancin—Skin disorder—Melphalan—ovarian cancer	0.0038	0.0038	CcSEcCtD
Oritavancin—Blood uric acid increased—Epirubicin—ovarian cancer	0.00375	0.00375	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—ovarian cancer	0.00375	0.00375	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—ovarian cancer	0.00367	0.00367	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00364	0.00364	CcSEcCtD
Oritavancin—Infestation NOS—Paclitaxel—ovarian cancer	0.0036	0.0036	CcSEcCtD
Oritavancin—Infestation—Paclitaxel—ovarian cancer	0.0036	0.0036	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—ovarian cancer	0.0036	0.0036	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.00357	0.00357	CcSEcCtD
Oritavancin—Urticaria—Chlorambucil—ovarian cancer	0.00356	0.00356	CcSEcCtD
Oritavancin—Myalgia—Vinorelbine—ovarian cancer	0.00356	0.00356	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00356	0.00356	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00354	0.00354	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.00349	0.00349	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—ovarian cancer	0.00347	0.00347	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00345	0.00345	CcSEcCtD
Oritavancin—Infection—Vinorelbine—ovarian cancer	0.00339	0.00339	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00337	0.00337	CcSEcCtD
Oritavancin—Bronchospasm—Docetaxel—ovarian cancer	0.00337	0.00337	CcSEcCtD
Oritavancin—Nervous system disorder—Vinorelbine—ovarian cancer	0.00335	0.00335	CcSEcCtD
Oritavancin—Tachycardia—Vinorelbine—ovarian cancer	0.00333	0.00333	CcSEcCtD
Oritavancin—Skin disorder—Vinorelbine—ovarian cancer	0.00332	0.00332	CcSEcCtD
Oritavancin—Hypersensitivity—Chlorambucil—ovarian cancer	0.0033	0.0033	CcSEcCtD
Oritavancin—Oedema peripheral—Paclitaxel—ovarian cancer	0.00319	0.00319	CcSEcCtD
Oritavancin—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00318	0.00318	CcSEcCtD
Oritavancin—Pruritus—Chlorambucil—ovarian cancer	0.00317	0.00317	CcSEcCtD
Oritavancin—Urticaria—Topotecan—ovarian cancer	0.00317	0.00317	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00311	0.00311	CcSEcCtD
Oritavancin—Urticaria—Melphalan—ovarian cancer	0.00311	0.00311	CcSEcCtD
Oritavancin—Diarrhoea—Chlorambucil—ovarian cancer	0.00307	0.00307	CcSEcCtD
Oritavancin—Erythema multiforme—Paclitaxel—ovarian cancer	0.00306	0.00306	CcSEcCtD
Oritavancin—Infestation—Docetaxel—ovarian cancer	0.00305	0.00305	CcSEcCtD
Oritavancin—Infestation NOS—Docetaxel—ovarian cancer	0.00305	0.00305	CcSEcCtD
Oritavancin—Cardiac disorder—Paclitaxel—ovarian cancer	0.003	0.003	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00295	0.00295	CcSEcCtD
Oritavancin—Hypersensitivity—Topotecan—ovarian cancer	0.00294	0.00294	CcSEcCtD
Oritavancin—Immune system disorder—Paclitaxel—ovarian cancer	0.00292	0.00292	CcSEcCtD
Oritavancin—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00291	0.00291	CcSEcCtD
Oritavancin—Hypersensitivity—Melphalan—ovarian cancer	0.00288	0.00288	CcSEcCtD
Oritavancin—Vomiting—Chlorambucil—ovarian cancer	0.00285	0.00285	CcSEcCtD
Oritavancin—Pruritus—Topotecan—ovarian cancer	0.00282	0.00282	CcSEcCtD
Oritavancin—Malnutrition—Paclitaxel—ovarian cancer	0.00281	0.00281	CcSEcCtD
Oritavancin—Pruritus—Melphalan—ovarian cancer	0.00277	0.00277	CcSEcCtD
Oritavancin—Hypoglycaemia—Epirubicin—ovarian cancer	0.00274	0.00274	CcSEcCtD
Oritavancin—Diarrhoea—Topotecan—ovarian cancer	0.00273	0.00273	CcSEcCtD
Oritavancin—Urticaria—Vinorelbine—ovarian cancer	0.00271	0.00271	CcSEcCtD
Oritavancin—Oedema peripheral—Docetaxel—ovarian cancer	0.0027	0.0027	CcSEcCtD
Oritavancin—Connective tissue disorder—Docetaxel—ovarian cancer	0.00269	0.00269	CcSEcCtD
Oritavancin—Diarrhoea—Melphalan—ovarian cancer	0.00267	0.00267	CcSEcCtD
Oritavancin—Nausea—Chlorambucil—ovarian cancer	0.00266	0.00266	CcSEcCtD
Oritavancin—Dizziness—Topotecan—ovarian cancer	0.00264	0.00264	CcSEcCtD
Oritavancin—Anaemia—Paclitaxel—ovarian cancer	0.0026	0.0026	CcSEcCtD
Oritavancin—Erythema multiforme—Docetaxel—ovarian cancer	0.00259	0.00259	CcSEcCtD
Oritavancin—Angioedema—Paclitaxel—ovarian cancer	0.00257	0.00257	CcSEcCtD
Oritavancin—Cardiac disorder—Docetaxel—ovarian cancer	0.00254	0.00254	CcSEcCtD
Oritavancin—Vomiting—Topotecan—ovarian cancer	0.00254	0.00254	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—ovarian cancer	0.00253	0.00253	CcSEcCtD
Oritavancin—Rash—Topotecan—ovarian cancer	0.00252	0.00252	CcSEcCtD
Oritavancin—Hypersensitivity—Vinorelbine—ovarian cancer	0.00252	0.00252	CcSEcCtD
Oritavancin—Dermatitis—Topotecan—ovarian cancer	0.00251	0.00251	CcSEcCtD
Oritavancin—Headache—Topotecan—ovarian cancer	0.0025	0.0025	CcSEcCtD
Oritavancin—Vomiting—Melphalan—ovarian cancer	0.00249	0.00249	CcSEcCtD
Oritavancin—Immune system disorder—Docetaxel—ovarian cancer	0.00248	0.00248	CcSEcCtD
Oritavancin—Mediastinal disorder—Docetaxel—ovarian cancer	0.00247	0.00247	CcSEcCtD
Oritavancin—Rash—Melphalan—ovarian cancer	0.00246	0.00246	CcSEcCtD
Oritavancin—Dermatitis—Melphalan—ovarian cancer	0.00246	0.00246	CcSEcCtD
Oritavancin—Pruritus—Vinorelbine—ovarian cancer	0.00242	0.00242	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00241	0.00241	CcSEcCtD
Oritavancin—Myalgia—Paclitaxel—ovarian cancer	0.0024	0.0024	CcSEcCtD
Oritavancin—Malnutrition—Docetaxel—ovarian cancer	0.00239	0.00239	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00238	0.00238	CcSEcCtD
Oritavancin—Nausea—Topotecan—ovarian cancer	0.00237	0.00237	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00236	0.00236	CcSEcCtD
Oritavancin—Diarrhoea—Vinorelbine—ovarian cancer	0.00234	0.00234	CcSEcCtD
Oritavancin—Nausea—Melphalan—ovarian cancer	0.00232	0.00232	CcSEcCtD
Oritavancin—Eosinophilia—Epirubicin—ovarian cancer	0.00229	0.00229	CcSEcCtD
Oritavancin—Infection—Paclitaxel—ovarian cancer	0.00228	0.00228	CcSEcCtD
Oritavancin—Dizziness—Vinorelbine—ovarian cancer	0.00226	0.00226	CcSEcCtD
Oritavancin—Nervous system disorder—Paclitaxel—ovarian cancer	0.00225	0.00225	CcSEcCtD
Oritavancin—Tachycardia—Paclitaxel—ovarian cancer	0.00224	0.00224	CcSEcCtD
Oritavancin—Skin disorder—Paclitaxel—ovarian cancer	0.00223	0.00223	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.00223	0.00223	CcSEcCtD
Oritavancin—Anaemia—Docetaxel—ovarian cancer	0.00221	0.00221	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.00218	0.00218	CcSEcCtD
Oritavancin—Vomiting—Vinorelbine—ovarian cancer	0.00217	0.00217	CcSEcCtD
Oritavancin—Rash—Vinorelbine—ovarian cancer	0.00215	0.00215	CcSEcCtD
Oritavancin—Dermatitis—Vinorelbine—ovarian cancer	0.00215	0.00215	CcSEcCtD
Oritavancin—Headache—Vinorelbine—ovarian cancer	0.00214	0.00214	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—ovarian cancer	0.00212	0.00212	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00209	0.00209	CcSEcCtD
Oritavancin—Infestation NOS—Epirubicin—ovarian cancer	0.00206	0.00206	CcSEcCtD
Oritavancin—Infestation—Epirubicin—ovarian cancer	0.00206	0.00206	CcSEcCtD
Oritavancin—Myalgia—Docetaxel—ovarian cancer	0.00203	0.00203	CcSEcCtD
Oritavancin—Nausea—Vinorelbine—ovarian cancer	0.00203	0.00203	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00202	0.00202	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00198	0.00198	CcSEcCtD
Oritavancin—Infection—Docetaxel—ovarian cancer	0.00193	0.00193	CcSEcCtD
Oritavancin—Nervous system disorder—Docetaxel—ovarian cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—ovarian cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—ovarian cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Tachycardia—Docetaxel—ovarian cancer	0.0019	0.0019	CcSEcCtD
Oritavancin—Skin disorder—Docetaxel—ovarian cancer	0.00189	0.00189	CcSEcCtD
Oritavancin—Urticaria—Paclitaxel—ovarian cancer	0.00182	0.00182	CcSEcCtD
Oritavancin—Oedema peripheral—Epirubicin—ovarian cancer	0.00182	0.00182	CcSEcCtD
Oritavancin—Connective tissue disorder—Epirubicin—ovarian cancer	0.00182	0.00182	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00177	0.00177	CcSEcCtD
Oritavancin—Erythema multiforme—Epirubicin—ovarian cancer	0.00175	0.00175	CcSEcCtD
Oritavancin—Cardiac disorder—Epirubicin—ovarian cancer	0.00172	0.00172	CcSEcCtD
Oritavancin—Hypersensitivity—Paclitaxel—ovarian cancer	0.00169	0.00169	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—ovarian cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Immune system disorder—Epirubicin—ovarian cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Mediastinal disorder—Epirubicin—ovarian cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Pruritus—Paclitaxel—ovarian cancer	0.00163	0.00163	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—ovarian cancer	0.00162	0.00162	CcSEcCtD
Oritavancin—Malnutrition—Epirubicin—ovarian cancer	0.00161	0.00161	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—ovarian cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Diarrhoea—Paclitaxel—ovarian cancer	0.00157	0.00157	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—ovarian cancer	0.00154	0.00154	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00154	0.00154	CcSEcCtD
Oritavancin—Dizziness—Paclitaxel—ovarian cancer	0.00152	0.00152	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—ovarian cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Anaemia—Epirubicin—ovarian cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Vomiting—Paclitaxel—ovarian cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Rash—Paclitaxel—ovarian cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Dermatitis—Paclitaxel—ovarian cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Headache—Paclitaxel—ovarian cancer	0.00144	0.00144	CcSEcCtD
Oritavancin—Hypersensitivity—Docetaxel—ovarian cancer	0.00143	0.00143	CcSEcCtD
Oritavancin—Pruritus—Docetaxel—ovarian cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—ovarian cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Myalgia—Epirubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Nausea—Paclitaxel—ovarian cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Diarrhoea—Docetaxel—ovarian cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Infection—Epirubicin—ovarian cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Nervous system disorder—Epirubicin—ovarian cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Dizziness—Docetaxel—ovarian cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Tachycardia—Epirubicin—ovarian cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Skin disorder—Epirubicin—ovarian cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00126	0.00126	CcSEcCtD
Oritavancin—Vomiting—Docetaxel—ovarian cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Rash—Docetaxel—ovarian cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Dermatitis—Docetaxel—ovarian cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Headache—Docetaxel—ovarian cancer	0.00122	0.00122	CcSEcCtD
Oritavancin—Infection—Doxorubicin—ovarian cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—ovarian cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—ovarian cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—ovarian cancer	0.00118	0.00118	CcSEcCtD
Oritavancin—Nausea—Docetaxel—ovarian cancer	0.00116	0.00116	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00113	0.00113	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00105	0.00105	CcSEcCtD
Oritavancin—Urticaria—Epirubicin—ovarian cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Hypersensitivity—Epirubicin—ovarian cancer	0.000968	0.000968	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—ovarian cancer	0.000965	0.000965	CcSEcCtD
Oritavancin—Pruritus—Epirubicin—ovarian cancer	0.000929	0.000929	CcSEcCtD
Oritavancin—Diarrhoea—Epirubicin—ovarian cancer	0.000899	0.000899	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—ovarian cancer	0.000895	0.000895	CcSEcCtD
Oritavancin—Dizziness—Epirubicin—ovarian cancer	0.000868	0.000868	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—ovarian cancer	0.00086	0.00086	CcSEcCtD
Oritavancin—Vomiting—Epirubicin—ovarian cancer	0.000835	0.000835	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—ovarian cancer	0.000831	0.000831	CcSEcCtD
Oritavancin—Rash—Epirubicin—ovarian cancer	0.000828	0.000828	CcSEcCtD
Oritavancin—Dermatitis—Epirubicin—ovarian cancer	0.000827	0.000827	CcSEcCtD
Oritavancin—Headache—Epirubicin—ovarian cancer	0.000823	0.000823	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—ovarian cancer	0.000804	0.000804	CcSEcCtD
Oritavancin—Nausea—Epirubicin—ovarian cancer	0.00078	0.00078	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—ovarian cancer	0.000773	0.000773	CcSEcCtD
Oritavancin—Rash—Doxorubicin—ovarian cancer	0.000766	0.000766	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—ovarian cancer	0.000765	0.000765	CcSEcCtD
Oritavancin—Headache—Doxorubicin—ovarian cancer	0.000761	0.000761	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—ovarian cancer	0.000722	0.000722	CcSEcCtD
